Silexion Therapeutics Corp (SLXN)

Silexion Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	9.24	1.19	4.6	8.26
Short-Term Investments	-	-	-	0.51
Cash & Short-Term Investments	9.24	1.19	4.6	8.77
Cash Growth	368.47%	-74.17%	-47.58%	-
Other Current Assets	1.81	1.06	0.38	0.07
Total Current Assets	11.06	2.25	4.98	8.84
Net Property, Plant & Equipment	0.47	0.56	0.25	0.46
Other Long-Term Assets	0.09	0.05	0.03	0.03
Total Assets	11.61	2.86	5.26	9.33
Accounts Payable	0.95	0.93	0.32	0.24
Accrued Expenses	1.67	1.43	1.57	1.25
Current Portion of Leases	0.17	0.16	0.11	0.12
Other Current Liabilities	-	1.01	0.2	0
Total Current Liabilities	2.79	3.52	2.2	1.61
Long-Term Debt	1.54	2.96	-	-
Long-Term Leases	0.31	0.37	0.06	0.16
Total Long-Term Liabilities	1.85	3.33	0.06	0.16
Total Liabilities	4.64	6.85	2.26	1.77
Total Common Shareholders' Equity	6.98	-3.99	-15.48	-10.67
Minority Interest	-	-	18.48	18.23
Shareholders' Equity	6.98	-3.99	3	7.57
Total Liabilities & Equity	11.61	2.86	5.26	9.33
Total Debt	2.03	3.49	0.17	0.27
Net Cash (Debt)	7.22	-2.3	4.42	8.5
Net Cash Growth	-	-	-47.92%	-
Net Cash Per Share	12.71	-55.24	590.42	1.14
Book Value	6.98	-3.99	-15.48	-10.67
Book Value Per Share	12.28	-95.81	-2065.39	-1.43
Tangible Book Value	6.98	-3.99	-15.48	-10.67
Tangible Book Value Per Share	12.28	-95.81	-2065.39	-1.43

Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q